Net launch prices for newly approved prescription drugs climbed sharply between 2022 and 2025, with the majority priced well above commonly accepted value benchmarks, according to a new nonprofit analysis. The findings arrive as public polling shows deep, bipartisan frustration with how little drug pricing is regulated, and as the federal government's first round of Medicare price negotiations moves toward implementation.

Launch Prices for New Medicines Climbed Sharply, Analysis Finds

A nonprofit research organization's new analysis concluded that net launch prices — the price drugmakers actually receive after rebates and discounts — rose significantly for new medicines introduced between 2022 and 2025. The analysis found that most of these newly launched drugs carried prices well above thresholds typically used to judge whether a treatment's cost is proportionate to its clinical benefit.

The trend adds to a growing body of research documenting escalating list and net prices for drugs entering the U.S. market, even as manufacturers argue that rebates, pharmacy benefit manager fees and other supply-chain costs eat into what they ultimately collect. High-profile recent approvals, including the first-of-its-kind treatment for chronic hepatitis B, illustrate the pattern: novel therapies for serious conditions often launch at premium prices that insurers, employers and patients are left to absorb.

Because launch prices set the baseline for a drug's entire time on the market — influencing insurance formularies, patient copays and eventual Medicare negotiation targets — researchers say the upward trend has long-term implications for overall health spending, even when individual drugs later become eligible for price controls.

Poll Finds Bipartisan Agreement That Drug Prices Are Under-Regulated

Separate polling released this year found that at least two-thirds of Democrats, independents and Republicans believe there is not enough government regulation of prescription drug prices. The consensus crosses party lines in a political environment where health policy is often sharply divided, underscoring how widely the cost of medications is felt across the electorate.

The sentiment comes as households already face rising health costs on multiple fronts, including the surge in employer insurance premiums expected in 2027 alongside falling ACA marketplace enrollment. Analysts say persistent public frustration over drug costs has kept pricing near the top of health policy debates heading into future election cycles, regardless of which party controls Washington.

Medicare Negotiation Program Advances, but Lower Prices Still Years Away

The Centers for Medicare & Medicaid Services confirmed that negotiations with drug manufacturers over a second round of selected medications are taking place in 2026, with any negotiated prices not becoming effective until 2028. The program, created to let Medicare directly negotiate prices for a limited list of high-cost drugs, represents one of the government's most significant recent interventions in drug pricing.

The multi-year lag between negotiation and implementation means patients and the broader health system won't see the financial benefits of this round for some time, even as the list of drugs subject to negotiation is expected to expand in future years. Supporters argue the program will eventually curb Medicare spending on some of the costliest medications, while industry groups continue to warn that it could discourage investment in new drug development.

Administration Touts Agency Cooperation on Affordability

Amid the data on rising launch prices, the administration has pointed to interagency collaboration as evidence of progress on affordability, crediting cooperation between drug regulatory and health agencies for recent wins on pricing. The messaging frames coordinated federal action as a model for further cost containment efforts.

The claim sits uneasily alongside the nonprofit pricing analysis and public opinion data showing continued dissatisfaction, highlighting a gap between official statements of progress and the lived experience of consumers still facing high costs for new medicines. How that tension is resolved — through expanded negotiation authority, transparency rules or market-based reforms — is likely to remain a central question in health policy debates in the months ahead.